Sign In
Buy AVXL
$2.65
-0.140 (-5.03%)
At Close: Jun 03, 2026
Anavex Life Sciences Reports Fiscal 2025 First Quarter Financial Results and Provides Business Update
07:30am, Wednesday, 12'th Feb 2025
Company to host a webcast t oday at 8:30 a.m. Eastern Time
Anavex Life Sciences to Announce Fiscal 2025 First Quarter Financial Results on Wednesday, February 12, 2025
07:30am, Wednesday, 05'th Feb 2025
Webcast and Conference Call To be Held Wednesday, February 12, 2025, 8:30 am ET Webcast and Conference Call To be Held Wednesday, February 12, 2025, 8:30 am ET
NEW YORK, Jan. 27, 2025 (GLOBE NEWSWIRE) -- Anavex Life Sciences Corp. (“Anavex” or the “Company”) (Nasdaq: AVXL), a clinical-stage biopharmaceutical company focused on developing innovative t
Anavex Life Sciences Stock Skyrockets 95% in 3 Months: Here's Why
12:01pm, Friday, 24'th Jan 2025
AVXL stock soars 95% in three months on positive updates from the development programs of its two clinical candidates, blarcamesine and ANAVEX 3-71.
Best Momentum Stocks to Buy for January 21st
11:11am, Tuesday, 21'st Jan 2025
CDNA, AVXL and ALNY made it to the Zacks Rank #1 (Strong Buy) momentum stocks list on January 21, 2025.
New Strong Buy Stocks for January 21st
07:45am, Tuesday, 21'st Jan 2025
CDNA, ALNY, ICL, AVXL and AA have been added to the Zacks Rank #1 (Strong Buy) List on January 21, 2025.
Blarcamesine potential novel oral treatment to target upstream Alzheimer's disease pathology through autophagy enhancement
Topline ATTENTION-AD trial: Patients showed improved cognition and function over three years Delayed-start analysis of treatment with oral blarcamesine was significant reflecting importance of early t
Playing The Odds Of Anavex Alzheimer's Drug Approval
11:21am, Sunday, 12'th Jan 2025
The EMA has accepted Anavex's Alzheimer's drug Blarcamesine for evaluation, with a decision expected by December 2025. Blarcamesine shows a 92% likelihood of approval by the EMA, yet investors have no
Here's Why 'Trend' Investors Would Love Betting on Anavex Life Sciences (AVXL)
09:51am, Tuesday, 07'th Jan 2025
Anavex Life Sciences (AVXL) could be a great choice for investors looking to make a profit from fundamentally strong stocks that are currently on the move. It is one of the several stocks that made it
Anavex Life Sciences to Present at the 43rd Annual J.P. Morgan Healthcare Conference
07:30am, Monday, 06'th Jan 2025
NEW YORK, Jan. 06, 2025 (GLOBE NEWSWIRE) -- Anavex Life Sciences Corp. (“Anavex” or the “Company”) (Nasdaq: AVXL), a clinical-stage biopharmaceutical company focused on developing innovative t
Are Medical Stocks Lagging Anavex Life Sciences (AVXL) This Year?
10:40am, Tuesday, 31'st Dec 2024
Here is how Anavex Life Sciences (AVXL) and AbbVie (ABBV) have performed compared to their sector so far this year.
All You Need to Know About Anavex Life Sciences (AVXL) Rating Upgrade to Buy
01:01pm, Monday, 30'th Dec 2024
Anavex Life Sciences (AVXL) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank #2 (Buy).
Anavex Life Sciences: Jumping In On-Time Ahead Early Alzheimer's Decision
07:30am, Friday, 27'th Dec 2024
Anavex Life Sciences' ANAVEX 2-73 shows promise in treating Alzheimer's, with strong efficacy in slowing cognitive and functional decline, and an attractive safety profile. The EMA has accepted ANAVEX
Short-Squeeze Target Anavex Life Sciences Gains Traction
07:30am, Thursday, 26'th Dec 2024
Anavex Life Sciences NASDAQ: AVXL is a short-squeeze candidate because its share prices are rising on good news, institutional and analyst support is growing, and the short-sellers are selling into th
